MiR-20a-5p reduces the sensitivity of nasopharyngeal carcinoma cells to radiotherapy by targeting NPAS2 and Rab27B, and miR-193a-3p enhances the anti-radiation ability of NPC by targeting SRSF2 43-45. Here, NPAS2 is linked to nasopharyngeal carcinoma.